The JAK2 V617F mutation in lung cancer: caveat emptor
As acquisition of the JAK2 V617F is considered to be restricted to myeloid malignancies, the recurrent identification of this mutation in non-small cell lung cancer (NSCLC) merits discussion, particularly in the light of accumulating evidence which suggests that the JAK2 V617F may...
Gespeichert in:
| Datum: | 2018 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | English |
| Veröffentlicht: |
PH Akademperiodyka
2018
|
| Schlagworte: | |
| Online Zugang: | https://exp-oncology.com.ua/index.php/Exp/article/view/2018-4-1 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Назва журналу: | Experimental Oncology |